Equities
  • Price (MXN)2,579.80
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-39.68%
  • Beta--
Data delayed at least 20 minutes, as of May 12 2022 15:53 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Masimo Corporation is a global medical technology company that develops, manufactures and markets a variety of noninvasive monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. Its patient monitoring solutions incorporates a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company provides its products to hospitals, emergency medical service (EMS) providers, home care providers, long-term care facilities, physician offices, veterinarians and consumers through direct sales force, distributors, and original equipment manufacturers partners. Its spot-check monitoring Pulse CO-Oximeters includes tetherless, wearable technology, such as Radius-7 and Radius PPG, portable devices, such as Rad-67 and MightySat Rx. Masimo Hospital Automation platform include iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet.

  • Revenue in USD (TTM)1.24bn
  • Net income in USD222.86m
  • Incorporated1996
  • Employees2.20k
  • Location
    Masimo Corp52 DiscoveryIRVINE 92618-3105United StatesUSA
  • Phone+1 (949) 297-7000
  • Fax+1 (949) 297-7499
  • Websitehttps://www.masimo.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MASI:NSQ since
announced
Transaction
value
Viper Holdings CorpDeal completed15 Feb 202215 Feb 2022Deal completed-39.07%1.03bn
Data delayed at least 15 minutes, as of May 18 2022 21:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.